Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0340
Trial ID NCT02965092
Disease Acute Lymphoblastic Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
Generation2nd
PhasePhase1|Phase2
Recruitment statusUnknown
TitleCD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Year2015
CountryChina
Company sponsorWuhan Sian Medical Technology Co., Ltd
Other ID(s)CART-CD19-01
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti-CD19 single-chain variable fragment; 4-1BB costimulatory domain
Vector production methodCD4+ and CD8+ T cells were picked out from PBMCs, which were acquired from patients by leukapheresis, with the use of magnetic beads (Miltenyi Biotec). The two kinds of T cells were separately cultured in bottles pre-coated with CD3 and CD28, with the existence of IL-2 and IFN-γ. They were transduced to CAR-T cells with lentivirus vectors encoding anti-CD19 single-chain variable fragment, 4-1BB costimulatory domain, etc. during the following 5 days. Next, the virus vectors would be washed away and tests to ensure effectivity and safety of CAR-T cells would be carried out. When desirable amounts of CD4+ and CD8+ CAR-T cells were attained, a mixture of them would be formed in a 1:1 ratio.

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 0.89~41E6 cells/kg
Donor type Autologous
Pts 53
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 47/53(CR)
Adverse reactions 19/53(cytokine release syndrome); 8/53(neurological toxicities)
References PMID: 31055613

Relationship Graph

Overview of Knowledge Graph